Sacral Neuromodulation in Patients With IC

Exclusion Criteria

• •Prior sacral neuromodulation.
• •Participant is currently pregnant or breastfeeding.
• •Male.
• •Urinary retention (defined by post void residual greater than 100cc).
• •Neurologic deficit.
• •Need for future MRI surveillance.
• •Involved in any study within the past thirty days or currently enrolled.
• •Presence of bladder or ureteral calculi.
• •Active genital herpes.
• •Uterine, cervical, vaginal, or urethral cancer.
• •Urethral diverticulum.
• •Cyclophosphamide cystitis.
• •Vaginitis.
• •Tuberculous cystitis.
• •Foreign body within the bladder (indwelling catheter- foley or suprapubic tube, or ureteral stent).
• •An employee or a relative of an employee of Medtronic Inc. or The Pelvic and Sexual Health Institute.
• •Bladder capacity greater than 350 cc while awake during cystometrogram.
• •Duration of symptoms of less than 6 months.
• •Detrusor overactivity on cystometrogram.
• •Absence of nocturia, defined by greater than 2 voids per sleeping hours.
• •Urinary symptoms relieved by either antimicrobials, antiseptics, anticholinergics, or antispasmodics.
• •Urinary frequency of less than 8 voids per day.
• •Diagnosis of bacterial cystitis or prostatitis within the past 3 months.
• •Radiation cystitis.
• •Benign or malignant bladder tumors.
• •Age less than 18 or greater than 79.
• •Participant is currently receiving or has received pelvic radiation.
• •Participant is diagnosed with cancer within the past 5 years prior to the start of the study.
• •Participant has a history of alcohol or substance abuse within the past 5 years prior to the start of the study.
• •Severe or uncontrolled diabetes or diabetes with peripheral nerve involvement.
• •Patients with implanted electrical devices (cardiac pacemakers or defibrillators).
• •Patients on anticoagulation therapy.
• •Planned future exposure to diathermy, microwave, or RF energy.